The U.S. Food and Drug Administration has issued an update on serious complications associated with transvaginal placement of surgical mesh for pelvic organ prolapse (POP), indicating these complications are not rare, according to a report from the FDA and AORN.
In addition, the update states it is not clear that transvaginal POP repair with mesh is more effective than traditional non-mesh repair in all patients with POP, and it actually may expose patients to greater risk.
This is a change from what the FDA previously indicated in Oct. 2008.
The FDA also indicated it is evaluating the effects of using surgical mesh to repair stress urinary incontinence.
Medical specialties impacted by this update include gynecology, urogynecology, urology, general surgery, internal medicine, family practice and emergency medicine.
Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!
Read the AORN report about this update and read the FDA report to learn updated recommendations for providers regarding surgical mesh for the transvaginal repair of POP.
Related Articles on Patient Safety:
Study: Longer Blood Storage Could Increase Risk of Infection, Other Complications
Clinical Statistics Surgery Centers Should Look at Every Month
7 Key Recommendations for Use of Personal Protective Equipment in Ambulatory Care Settings